At the news
? NEUTRALIMPACT 5/10 6-K filed Sep 1, 2026 at 07:10 ET
AstraZeneca completed its previously announced exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for NSCLC with exon 20 insertion mutations. AstraZeneca paid $600M upfront with up to $900M in milestones plus tiered royalties, gaining worldwide rights to a drug already approved in the US and China for 2nd-line treatment and under FDA review for 1st-line use. The deal strengthens AstraZeneca's lung cancer portfolio but the $600M upfront and potential $1.5B total consideration represent a material cash outlay with no near-term revenue contribution, and the company stated it does not impact 2026 financial guidance.
- AstraZeneca completed an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for NSCLC.
- AstraZeneca made a $600M upfront payment to Dizal, with up to $900M in additional milestone payments and tiered royalties on global sales.
- Zegfrovy is already approved in the US and China for 2nd-line treatment of NSCLC with EGFR exon 20 insertion mutations.
- A supplemental NDA for 1st-line use has been accepted by the FDA, supported by positive Phase III WU-KONG28 trial data.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access